SAN AN­TO­NIO — No­vo Nordisk’s wild­ly pop­u­lar an­ti-obe­si­ty drug We­govy helped heart dis­ease pa­tients end up in the ...

CinFina Pharma, a subsidiary of the hub-and-spoke biotech CinRx, shared early-stage data for two of its Janssen-licensed ...

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...

A panel of three judges on the US Court of Appeals for the Third Circuit didn't offer too many hints at which side it would ...

Maven Clinic laid off 60 people on Monday, Endpoints News has learned. The layoffs at the unicorn health tech startup ...

Generic drug manufacturers Heritage Pharmaceuticals and Apotex have agreed to pay $49.1 million to settle allegations from ...

A day after Madrigal Pharmaceuticals impressed investors, Novo Nordisk is looking to steal the spotlight. The Danish ...

Plus, news about Kymera Therapeutics, Nanoscope, Eupraxia, Alpha Cognition and EyePoint: FDA lifts hold of CARsgen’s CAR-T therapies: The FDA on Thursday lifted a clinical hold ...

Baxter has “suspended commercial activities” of its intravenous products in China to ease supply issues in the US caused by ...

Essa Pharma is exploring “strategic options” as it ends work on its prostate cancer drug that failed a mid-stage test. The company's shares {$EPIX} nosedived by as much as 65 ...

Michael McDonnell is retiring as CFO of Biogen on Feb. 28, and Chris Viehbacher’s crew has lined up chief accounting officer Robin Kramer as his replacement. Peer Review covered ...

UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint. Neither the low dose nor high dose resulted in patients ...